Stock Financial Ratios, Dividends, Split History
CNFR / Conifer Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||55.38|
|Enterprise Value ($M)||72.15|
|Book Value ($M)||51.42|
|Book Value / Share||6.04|
|Price / Book||1.12|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Income Statement (mra) ($M)|
|Management Fees Revenue||0.00|
|Sales Revenue Net||93,289,000.00|
|Earnings Per Share Diluted||-2.74|
|Earnings Per Share Basic And Diluted||-2.74|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||9.09|
|Cash from Investing||-25.95|
|Cash from Financing||-25.95|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1502292|
|SIC 6331 - Fire, Marine, and Casualty Insurance|
Stock splits are used by Conifer Holdings, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
The current economic backdrop is shaping up well for insurers as they are witnessing gradual improvement in interest rates along with substantially lower level of catastrophe loss and reduced tax (owing to a noteworthy tax reform effective Jan 1, 2018). These factors have also led to a promising performance in the first quarter of 2018 and augur well for an encouraging second quarter. Hence, we expect the insurance industry to continue with the momentum and deliver a better-than-expected show as the year progresses.
A recent report by Insurance Information Institute stated that the 2018 Atlantic hurricane season is expected to be milder than the earlier forecast. This is a relief for insurers since they faced above-average catastrophe activity in 2017 and incurred billions in losses from claim costs. (1-0)
The Zacks Property and Casualty industry is currently undervalued compared with the S&P 500 index. The price-to-book (P/B) ratio, the best multiple for valuing insurers because of their unpredictable financial results, is 1.4, less than the broader market’s P/B of 3.9. Such below market positioning hints at room for upside in the coming quarters. (9-0)
Good morning everyone and welcome to the Conifer Holdings First Quarter 2018 Investor Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note that today's event is being recorded. And I would now like to turn the conference over to Adam Prior with The Equity Group. (1-0)
as of ET